All News
Filter News
Found 808,462 articles
-
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
4/17/2024
Windtree Therapeutics, Inc. today reported financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided key business updates.
-
Ventus Therapeutics Announces Results from Phase 1 Clinical Trial of VENT-02, a Novel, Orally Administered, Brain-Penetrant NLRP3 Inhibitor
4/17/2024
Ventus Therapeutics today announced results from its Phase 1 clinical trial of VENT-02, a novel, oral, brain-penetrant NLRP3 inhibitor.
-
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®
4/17/2024
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that the Aesthetic Surgery Journal has published the safety and duration of effect results from the Phase 2 study of 40U Jeuveau® (prabotulinumtoxinA-xvfs) for the treatment of moderate to severe glabellar lines in adult patients.
-
NRx Pharmaceuticals, Inc. Announces New Data on NRX-101
4/17/2024
NRx Pharmaceuticals today announced new data that demonstrate that in a rodent model NRX-101 shows no measurable damage to either intestinal or vaginal flora, compared to the significant negative effect caused by drugs such as ciprofloxacin.
-
Outset Medical and U.S. Renal Care Announce Multi-Year Agreement to Accelerate and Grow Home Dialysis Across the U.S.
4/17/2024
Outset Medical, Inc. announced today a multi-year agreement to help accelerate home hemodialysis in the U.S.
-
Allurion Closes $48 Million Convertible Senior Secured Note Financing with RTW Investments
4/17/2024
Allurion Technologies, Inc. today announced the closing of a $48 million convertible senior secured note financing with certain entities managed by RTW Investments, LP (“RTW”).
-
Annual General Meeting of Kuros Biosciences Approves All Resolutions
4/17/2024
Kuros Biosciences (SIX:KURN), a leader in next generation bone graft technologies, held its Annual General Meeting today.
-
Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds
4/17/2024
Longeveron Inc. today announced that it has entered into definitive agreements for the exercise of certain existing warrants to purchase an aggregate of 2,399,744 shares.
-
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
4/17/2024
Immutep Limited today announces it has received positive feedback from the Spanish Agency for Medicines and Health Products (AEMPS) Competent Authority regarding the Company’s upcoming TACTI-004 Phase III trial of eftilagimod alpha (“efti”) for first line treatment of metastatic non-small cell lung cancer (1L NSCLC).
-
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
4/17/2024
Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that patient enrollment has been completed in the Company’s Phase 2 clinical study of barzolvolimab for the treatment of the two most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD).
-
Recce Pharmaceuticals Completes 5,000 RECCE® 327 Doses a Week under Good Manufacturing Practice (GMP)
4/17/2024
Recce Pharmaceuticals Ltd today announced the successful batch completion under Good Manufacturing Practices (GMP) for its lead candidate, RECCE® 327 (R327), with the patented manufacturing process now producing 5,000 GMP doses of R327 per week.
-
Delve Bio presents study showing utility of metagenomic next generation sequencing (mNGS) in diagnosing neurological infections
4/17/2024
Delve Bio in collaboration with the University of California, San Francisco (UCSF), today announced data on the use of mNGS for the diagnosis of infectious causes of meningitis and/or encephalitis in real-world clinical settings.
-
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
4/17/2024
Stoke Therapeutics, Inc. today announced the appointment of Jason Hoitt as Chief Commercial Officer.
-
Psyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR)
4/17/2024
Psyence Biomedical Ltd today announced that details of its upcoming Phase IIb clinical trial of nature-derived psilocybin in patients diagnosed with Adjustment Disorder following an advanced cancer diagnosis in the Palliative Care context has been listed on the Australian New Zealand Clinical Trials Registry (“ANZCTR”), under registration number 12624000449538p.
-
Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
4/17/2024
Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced an exclusive licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem.
-
Bionano and Diagens Sign Partnership to Commercialize the First Ever Clinical Cytogenetic Analysis that Combines OGM and Artificial Intelligence
4/17/2024
Bionano Genomics, Inc. (BNGO), a global leader in the transformation of the cytogenetic workflow with OGM, today announced that it has entered into an original equipment manufacturing (OEM) partnership agreement with Diagens, an assisted reproductive technology company based in China focused on the application of AI in cytogenetics.
-
Sensorium Therapeutics Appoints Sam Rasty as Chief Business Officer
4/17/2024
Sensorium Therapeutics today announced the appointment of Sam Rasty, Ph.D., as Chief Business Officer.
-
Aspen Neuroscience Announces First Patient Dosed in First-in-Human Phase 1/2a Clinical Trial of Autologous Neuronal Cell Replacement Therapy for Parkinson's Disease
4/17/2024
Aspen Neuroscience, Inc. announced that the first patient has been dosed in the ASPIRO trial, a Phase 1/2a open label clinical trial to assess safety and tolerability of ANPD001, an autologous, dopaminergic neuron cell replacement therapy for participants with moderate to severe Parkinson's disease (PD).
-
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
4/17/2024
NeuroBo Pharmaceuticals, Inc. today announced dosing of the first patient in the single ascending dose (SAD) Part 1 of its two-part Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity.
-
Saghmos Therapeutics Announces Collaboration with Duke Clinical Research Institute to Optimize Phase 3 Cardio-Renal Metabolic Study
4/17/2024
Saghmos Therapeutics, Inc. (Saghmos), a privately held biopharmaceutical company, announced it will partner with the Duke Clinical Research Institute (DCRI) to optimize all aspects of and plan the operationalization of Saghmos’ Phase 3 study for its cardio-renal metabolic modulator ST-62516.